News and Trends 10 Nov 2022
Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies
Precision oncology company, Parthenon Therapeutics, and ImaginAb Inc., a global biotech have entered into a multi-year, non-exclusive license and supply agreement. Under the agreement terms, Parthenon will use ImaginAb’s CD8…